Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S003329172200085X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.
Neuropsychopharmacology
December 2024
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TRD) in order to facilitate evidence-based choices. A literature search of PubMed, Cochrane Library, and Embase from inception until April 13th, 2023 identified randomized, controlled trials (RCTs) of adults with depression who had not responded to at least two antidepressant trials; all RCTs had ≥10 participants per study arm, and participants with bipolar or psychotic depression were excluded. The Cochrane Risk of Bias Tool-2 was used to assess study quality.
View Article and Find Full Text PDFClinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs : Une étude de population transversale.
Can J Psychiatry
November 2024
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Objective: Electroconvulsive therapy (ECT) is an evidence-based treatment for schizophrenia when anti-psychotic medications do not sufficiently control symptoms of psychosis or rapid response is required. Little is known about how it is used in routine clinical practice. The aim of this study was to identify the association of demographic and clinical characteristics with administration of ECT for schizophrenia spectrum disorders (SSD).
View Article and Find Full Text PDFThe electro-convulsive therapy story of Africa, a systematic review.
Discov Ment Health
September 2024
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Canada.
Over the years, the use of Electroconvulsive therapy (ECT) has gained increasing acceptance as a viable treatment for managing treatment-resistant mental health conditions, and it is known to deliver more rapid therapeutic benefits than most treatment modalities in psychiatry. However, the practice of ECT exhibits significant variability both within and between countries. This review aimed to shed light on the status of ECT in the African context and its implications for mental health care in the region.
View Article and Find Full Text PDFThe Sensitivity of the Mini-Mental State Examination to Detect Objective Cognitive Side Effects Induced by Electroconvulsive Therapy: Results From the Dutch ECT Consortium.
Biol Psychiatry Cogn Neurosci Neuroimaging
August 2024
Department of Psychology, Brain and Cognition, University of Amsterdam, Amsterdam, the Netherlands; Department of Medical Psychology, Amsterdam UMC, Amsterdam, the Netherlands; ECT Department, Parnassia Psychiatric Institute, The Hague, the Netherlands.
Background: Monitoring cognitive side effects following electroconvulsive therapy (ECT) is crucial for balancing side effects and clinical effectiveness. Yet, evidence-based guidelines on cognitive testing following ECT are lacking. A frequently used test in global ECT practice is the Mini-Mental State Examination (MMSE).
View Article and Find Full Text PDFEfficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.
Psychiatry Res
September 2024
School of Nursing, Peking University, Beijing, China. Electronic address:
Background: Treatment-Resistant Depression (TRD) challenges psychiatric treatment, with existing guidelines covering only a subset of augmentation strategies.
Methods: A network meta-analysis following PRISMA guidelines examined the efficacy and safety of TRD treatments, analyzing 72 randomized controlled trials from eight databases, assessing response and remission rates, tolerability, and safety through the Cochrane Risk of Bias Tool and CINeMA framework.
Findings: Including 12,105 participants, the analysis highlighted ECT, Ketamine, Esketamine, and Psilocybin as superior first-line treatments due to their optimal balance between effectiveness and tolerability.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!